Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information
By Denny Jacob
Boston Scientific and Axonics each received a request for additional information from the Federal Trade Commission regarding a previously agreed upon merger.
The medical device manufacturer in January agreed to acquire Axonics for about $3.7 billion in cash, resulting in Axonics becoming a wholly-owned subsidiary of Boston Scientific.
The additional request for information extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after both sides have substantially complied with the request, Boston Scientific said in a securities filing.
The merger is now expected to be completed in the second half of 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 04, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations